Search results
FDA reverses course, calls for vaccines for fall 2024 to target newer COVID-19 strain
Scripps News via AOL· 2 days agoThe FDA is reversing course on its COVID vaccine guidance: Rather than having a vaccine that targets...
Household study suggests infants may spread C difficile
Center for Infectious Disease Research and Policy· 2 days agoA longitudinal household study found shared C difficile strains in 17 of 28 families, with the...
Past COVID infections may help protect against certain colds. Could it lead to better vaccines?
Medical Xpress· 3 days agoIf you've been sick with COVID-19, you may have some protection against certain versions of the...
Summer surge? South Bay health officials keep close eye on COVID-19 concentrations
NBC Bay Area· 3 days agoThe Santa Clara County Public Health Department said it is seeing the start of what may be a summer...
Past COVID infections may help protect against certain colds. Could it lead to better vaccines?
San Francisco Chronicle· 3 days agoIf you’ve been sick with COVID-19, you may have some protection against certain versions of the...
US government to fund up to $500 mln for studies on oral, nasal COVID vaccines
Reuters· 2 days agoThe U.S. Department of Health and Human Services (HHS) said on Thursday it will provide up to $500...
US government to fund up to $500 million for studies on oral, nasal COVID vaccines
Reuters via Yahoo News· 2 days agoThe funding is part of Project NextGen, a $5 billion initiative led by the Biomedical Advanced Research and Development Authority (BARDA), to advance a pipeline of new, innovative vaccines and ...
Xencor (NASDAQ:XNCR) Price Target Cut to $40.00 by Analysts at Raymond James
ETF DAILY NEWS· 23 hours agoXencor (NASDAQ:XNCR – Free Report) had its target price lowered by Raymond James from $58.00 to $40.00 in a research report report published on Friday, Benzinga reports. The firm currently has ...
Past COVID infections may help protect against certain colds. Could it lead to better vaccines?
WPRI Providence· 3 days agoIf you’ve been sick with COVID-19, you may have some protection against certain versions of the...
CyanVac secures funding for Phase IIb intranasal Covid-19 vaccine trial
Clinical Trials Arena via Yahoo Finance· 2 days agoCyanVac and its affiliate Blue Lake Biotechnology are developing the single-dose, intranasal vaccine...